Piperonylonitrile

4421-09-4

Chenglian Pharmaceutical is an innovative high-tech pharmaceuti"cal enterprise that is market-oriented and realizes industrial development th'rough R&D innovation and technology transformation.

key word:

technology Pharmaceutical

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry fin≠ance platform company integrating pharmaceutical, i®ntelligent medical, bio pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products inclu₽de Foucault reaction, nitration reaction, sulfonation reaction, hydrogenation ×reaction, fluorination reaction, chlorination reaction, bromination reαaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck₹. In October 2006, Sitagliptin phosphate Januvia w✘as approved by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The₩ characteristics of this drug are that it can stimulate insulin secre tion while reducing hunger without causing weight gain. Hypoglycemia and ede<ma will not occur, and it is suitable for diabetic patients with poor blood g£lucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise  that is market-oriented and realizes industrial development through R&D i→nnovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen i©s one of the most important products for the treatment of εarthritis. It is well tolerated and has a low incidenceα of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene ≈receptor antagonists. In clinical application, it has good therapeutic effect on atopic asthma an<d other types of bronchial asthma, and the market prospect is hαuge. In the major category of asthma drugs, leukotriene receptor &antagonists have the fastest growing market share.‍

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise th♣at is market-oriented and realizes industrial deve∞lopment through R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the secon‌d drug approved by FDA for Alzheimer's disease in the United StateΩs. Its treatment reaches the target dose and has low toxic and side effect×s. It has been widely recognized by our medical community, and good tolerβance is its biggest advantage. In October 1999, Donepez‌il was launched in China under the trade name "Aricept", which is the main chemical drug againstβ Alzheimer's disease. At present, CFDA has approved a numb‌er of domestic enterprises to produce donepezil preparations, the main dosage forms a←re tablets, capsules, dispersive tablets, oral disintegrating tablets↓.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myλers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use  in the 27 EU member states. The world's first drug approved ×to prevent venous thromboembolism (VTE) in adult patients un↓dergoing elective hip or knee replacement. From June ≥2019 to June 2020, the annual sales of apixaban products overseas reached about $15.4 biπllion, with a year-on-year growth of nearly 32%, and the API consumption reached about ₩23,960 kg, with a year-on-year growth of about 28%. Compared wi‍th its main competitor, Rivaroxaban, the drug's annual overseas sales are about $4.5 billion "higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharma₩ceutical enterprise that is market-oriented and realizes industrial d‌evelopment through R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by ♦Genzyme. On December 29, 2004, it was approved by FDA for the treatment of ref£ractory or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is∞ market-oriented and realizes industrial development through R&D innovation and techn∞ology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If& you need other services, E-mail: 2880705932@qq.com